Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Afb, OH
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Afb, OH
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Geisinger Medical Center
mi
from
Danville, PA
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Geisinger Medical Group
mi
from
State College, PA
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Geisinger Medical Group
mi
from
State College, PA
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Rose Ramer Cancer Clinic at Anderson Area Medical Center
mi
from
Anderson, SC
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Rose Ramer Cancer Clinic at Anderson Area Medical Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Luther Mildelfort Hospital
mi
from
Eau Claire, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Luther Mildelfort Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Green Bay Oncology, Limited at St. Vincent Hospital
mi
from
Green Bay, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Green Bay Oncology, Limited at St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
St. Vincent Hospital
mi
from
Green Bay, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
St. Mary's Hospital Medical Center
mi
from
Green Bay, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
St. Mary's Hospital Medical Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated:  7/7/2015
Welch Cancer Center
mi
from
Sheridan, WY
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients
Status: Enrolling
Updated: 7/7/2015
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Lombardi Cancer Center
mi
from
Washington,
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Walter Reed Army Medical Center
mi
from
Washington,
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
University of Massachusetts Memorial Medical Center - University Campus
mi
from
Worcester, MA
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
University of Massachusetts Memorial Medical Center - University Campus
mi
from
Worcester, MA
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/7/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/7/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials